Deal

BIO-RAD LABORATORIES, INC. acquires QuantaLife, Inc.

October 2011 full acquisition ready

Snapshot

BIO-RAD LABORATORIES, INC. acquired QuantaLife, Inc. for $179.4 million fair value of consideration ($150.3 million cash at closing, $5.0 million holdback, $24.1 million contingent consideration; contingent portion could reach $48 million on sales and development milestones) in October 2011. The transaction was structured as all cash plus contingent consideration. QuantaLife, Inc. is a Life Science business.

Acquirer
BIO-RAD LABORATORIES, INC.
Target
QuantaLife, Inc.
Value
$179.4 million fair value of consideration ($150.3 million cash at closing, $5.0 million holdback, $24.1 million contingent consideration; contingent portion could reach $48 million on sales and development milestones)
Date
October 2011
Type
full acquisition
Status
ready
01 Scorecard

The deal at a glance

Private-market deal
BIO-RAD LABORATORIES, INC. acquires QuantaLife, Inc.
Deal value
$179.4 million fair value of consideration ($150.3 million cash at closing, $5.0 million holdback, $24.1 million contingent consideration; contingent portion could reach $48 million on sales and development milestones)
Sector
Life Science
Date
October 2011
VectorShift
Made on VectorShift

About this deal

BIO-RAD LABORATORIES, INC. acquired QuantaLife, Inc. for $179.4 million fair value of consideration ($150.3 million cash at closing, $5.0 million holdback, $24.1 million contingent consideration; contingent portion could reach $48 million on sales and development milestones), a transaction completed in October 2011, structured as all cash plus contingent consideration.

QuantaLife, Inc. operates in Life Science. QuantaLife developed droplet digital PCR technology that became the foundation of Bio-Rad's droplet digital PCR (ddPCR) systems.

QuantaLife's droplet digital PCR technology formed the core of Bio-Rad's ddPCR product line.

Pioneering droplet digital PCR platform that established Bio-Rad's ddPCR franchise. Launched Bio-Rad's droplet digital PCR (ddPCR) product line within the Life Science segment. Life Science segment

In October 2011, we acquired all the issued and outstanding stock of QuantaLife, Inc. The fair value of the consideration as of the acquisition date was $179.4 million, which comprised of $150.3 million paid in cash at the closing date, a $5.0 million holdback... and $24.1 million in contingent consideration.
Bio-Rad Laboratories FY2011 10-K, acquisitions disclosure
Advisors not disclosed

No advisory firms have been disclosed for this transaction.

Sources Press release Last updated

Related deals & entities

Related dealBIO-RAD LABORATORIES, INC. / DiaMed Holding AG Related dealBIO-RAD LABORATORIES, INC. / Stilla Technologies Related dealBIO-RAD LABORATORIES, INC. / Curiosity Diagnostics sp. z o.o. Related dealBIO-RAD LABORATORIES, INC. / Dropworks, Inc. Related dealBIO-RAD LABORATORIES, INC. / Celsee, Inc. Related dealBIO-RAD LABORATORIES, INC. / RainDance Technologies, Inc.

See how VectorShift works for your firm

Request Demo